Belsomra (suvorexant), a new class of drug for treatment of insomnia developed by Merck & Co., has been placed in Schedule IV (79 Fed. Reg. 51243; Aug. 28, 2014). Unlike other prescription sleep-aids, Belsomra inhibits wakefulness rather than inducing sleep. It has already been approved by the U.S. Food and Drug Administration and was awaiting Drug Enforcement Administration s... Read More